LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 42

Search options

  1. Article ; Online: Challenges in Modeling Hemodynamics in Cerebral Aneurysms Related to Arteriovenous Malformations.

    Boster, Kimberly A Stevens / Shidhore, Tanmay C / Cohen-Gadol, Aaron A / Christov, Ivan C / Rayz, Vitaliy L

    Cardiovascular engineering and technology

    2022  Volume 13, Issue 5, Page(s) 673–684

    Abstract: Purpose: The significantly higher incidence of aneurysms in patients with arteriovenous malformations (AVMs) suggests a strong hemodynamic relationship between these lesions. The presence of an AVM alters hemodynamics in proximal vessels by drastically ... ...

    Abstract Purpose: The significantly higher incidence of aneurysms in patients with arteriovenous malformations (AVMs) suggests a strong hemodynamic relationship between these lesions. The presence of an AVM alters hemodynamics in proximal vessels by drastically changing the distal resistance, thus affecting intra-aneurysmal flow. This study discusses the challenges associated with patient-specific modeling of aneurysms in the presence of AVMs.
    Methods: We explore how the presence of a generic distal AVM affects upstream aneurysms by examining the relationship between distal resistance and aneurysmal wall shear stress using physiologically realistic estimates for the influence of the AVM on hemodynamics. Using image-based computational models of aneurysms and surrounding vasculature, aneurysmal wall-shear stress is calculated for a range of distal resistances corresponding to the presence of AVMs of various sizes and compared with a control case representing the absence of an AVM.
    Results: In the patient cases considered, the alteration in aneurysmal wall shear stress due to the presence of an AVM is considerable, as much as 19 times the base case wall shear stress. Furthermore, the relationship between aneurysmal wall shear stress and distal resistance is shown to be highly geometry-dependent and nonlinear. In most cases, the range of physiologically realistic possibilities for AVM-related distal resistance are so large that patient-specific flow measurements are necessary for meaningful predictions of wall shear stress.
    Conclusions: The presented work offers insight on the impact of distal AVMs on aneurysmal wall shear stress using physiologically realistic computational models. Patient-specific modeling of hemodynamics in aneurysms and associated AVMs has great potential for understanding lesion pathogenesis, surgical planning, and assessing the effect of treatment of one lesion relative to another. However, we show that modeling approaches cannot usually meaningfully quantify the impact of AVMs if based solely on imaging data from CT and X-ray angiography, currently used in clinical practice. Based on recent studies, it appears that 4D flow MRI is one promising approach to obtaining meaningful patient-specific flow boundary conditions that improve modeling fidelity.
    MeSH term(s) Humans ; Intracranial Aneurysm/therapy ; Intracranial Arteriovenous Malformations/complications ; Intracranial Arteriovenous Malformations/diagnostic imaging ; Hemodynamics/physiology ; Magnetic Resonance Imaging ; Stress, Mechanical
    Language English
    Publishing date 2022-02-01
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 2543111-0
    ISSN 1869-4098 ; 1869-408X
    ISSN (online) 1869-4098
    ISSN 1869-408X
    DOI 10.1007/s13239-022-00609-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Intracerebral haemorrhage during alemtuzumab administration.

    Azevedo, Christina J / Kutz, Christen / Dix, Amy / Boster, Aaron / Sanossian, Nerses / Kaplan, Jeffrey

    The Lancet. Neurology

    2019  Volume 18, Issue 4, Page(s) 329–331

    MeSH term(s) Adult ; Alemtuzumab/adverse effects ; Alemtuzumab/therapeutic use ; Blood Pressure/drug effects ; Cerebral Hemorrhage/chemically induced ; Cerebral Hemorrhage/drug therapy ; Female ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Multiple Sclerosis, Relapsing-Remitting/complications ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Retrospective Studies ; Risk Factors
    Chemical Substances Alemtuzumab (3A189DH42V)
    Language English
    Publishing date 2019-02-15
    Publishing country England
    Document type Letter
    ZDB-ID 2081241-3
    ISSN 1474-4465 ; 1474-4422
    ISSN (online) 1474-4465
    ISSN 1474-4422
    DOI 10.1016/S1474-4422(19)30076-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist.

    Fox, Edward J / Buckle, Guy J / Singer, Barry / Singh, Vibhuti / Boster, Aaron

    Neurology. Clinical practice

    2019  Volume 9, Issue 1, Page(s) 53–63

    Abstract: Purpose of review: To provide neurologists with an update on the proposed mechanisms of action (MOAs) of disease-modifying therapies (DMTs) for the treatment of relapsing MS, and their effect on peripheral blood leukocytes, in order to inform treatment ... ...

    Abstract Purpose of review: To provide neurologists with an update on the proposed mechanisms of action (MOAs) of disease-modifying therapies (DMTs) for the treatment of relapsing MS, and their effect on peripheral blood leukocytes, in order to inform treatment decisions.
    Recent findings: DMTs have vastly differing MOAs, including effects on peripheral blood leukocyte counts, particularly lymphocytes. The clinical implications of changes in lymphocyte counts need to be understood in the context of the underlying MOAs of each respective DMT, with treatment tailored to individual patient needs.
    Summary: DMTs can alter lymphocyte counts, subsets, activation, and distribution, and thus can influence immune surveillance. Serial monitoring of total leukocytes and absolute lymphocyte counts (ALCs) is advisable in patients receiving DMTs. ALCs should be interpreted regarding expected immunologic changes and individual patient characteristics. Any decision to switch DMTs should consider these factors, along with drug efficacy, safety, and effect on quality of life.
    Language English
    Publishing date 2019-03-05
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2645818-4
    ISSN 2163-0933 ; 2163-0402
    ISSN (online) 2163-0933
    ISSN 2163-0402
    DOI 10.1212/CPJ.0000000000000567
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Managing loss of intrathecal baclofen efficacy: Review of the literature and proposed troubleshooting algorithm.

    Boster, Aaron / Nicholas, Jacqueline / Bartoszek, Mary Pat / O'Connell, Colleen / Oluigbo, Chima

    Neurology. Clinical practice

    2017  Volume 4, Issue 2, Page(s) 123–130

    Abstract: Spasticity is a debilitating symptom associated with numerous neurologic conditions. While intrathecal baclofen therapy (ITB) is an established treatment for spasticity, complications can lead to loss of efficacy (LOE) and baclofen withdrawal. Untreated ... ...

    Abstract Spasticity is a debilitating symptom associated with numerous neurologic conditions. While intrathecal baclofen therapy (ITB) is an established treatment for spasticity, complications can lead to loss of efficacy (LOE) and baclofen withdrawal. Untreated withdrawal syndrome can be fatal. Prompt diagnosis and management of LOE is essential. Numerous methods have been described in the literature for diagnosing the cause of LOE. Many of the methods require equipment not readily available in the outpatient setting. Furthermore, there is no established consensus on the sequencing of these diagnostic tests. Herein, we review ITB literature on troubleshooting LOE for applicability to the managing clinician. Using this information and our clinical experience, we propose an algorithm with management recommendations to simplify and expedite the troubleshooting process in the outpatient setting.
    Language English
    Publishing date 2017-06-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2645818-4
    ISSN 2163-0933 ; 2163-0402
    ISSN (online) 2163-0933
    ISSN 2163-0402
    DOI 10.1212/cpj.0000000000000000
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.

    Bass, Ann D / Van Wijmeersch, Bart / Mayer, Lori / Mäurer, Mathias / Boster, Aaron / Mandel, Matt / Mitchell, Colin / Sharrock, Kersten / Singer, Barry

    International journal of MS care

    2019  Volume 22, Issue 4, Page(s) 158–164

    Abstract: Background: The vsMS survey was conducted to better understand the negative effects of fatigue, cognitive impairment, emotional burden, and decreased physical functioning on the personal, professional, and social lives of individuals with multiple ... ...

    Abstract Background: The vsMS survey was conducted to better understand the negative effects of fatigue, cognitive impairment, emotional burden, and decreased physical functioning on the personal, professional, and social lives of individuals with multiple sclerosis (MS).
    Methods: The vsMS survey was an online survey conducted in Australia, Canada, France, Italy, Spain, the United Kingdom, and the United States that assessed the impact of MS on individuals' daily activities, emotional well-being, relationships, and employment.
    Results: The survey included 1075 participants with relapsing-remitting MS. Almost 42% of participants reported that their ability to perform and manage daily activities had worsened during the previous 2 years. More than 50% reported limitations in daily activities due to fatigue, physical weakness, problems with balance/coordination, heat/cold sensitivity, memory problems, numbness/tingling, trouble concentrating, impaired movement/muscle stiffness, and impaired sleeping. Participants also reported a negative effect on emotional and social factors, including self-esteem, general outlook, well-being, maintaining/starting relationships, ability to progress in their career/keep their job, and ability to cope with life roles.
    Conclusions: These data highlight the importance of addressing the impact of MS and the social and emotional disease burdens on daily activities when planning the care of patients with MS.
    Language English
    Publishing date 2019-08-28
    Publishing country United States
    Document type Journal Article
    ISSN 1537-2073
    ISSN 1537-2073
    DOI 10.7224/1537-2073.2018-087
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Multiple sclerosis: Five new things.

    Nicholas, Jacqueline A / Boster, Aaron L / Racke, Michael K

    Neurology. Clinical practice

    2013  Volume 3, Issue 5, Page(s) 404–412

    Abstract: Preliminary studies have suggested that a high salt diet may play a role in the development of autoimmune disease and possibly multiple sclerosis (MS). Promising clinical trial results for 2 new therapies for MS have been reported. Dimethyl fumarate, ... ...

    Abstract Preliminary studies have suggested that a high salt diet may play a role in the development of autoimmune disease and possibly multiple sclerosis (MS). Promising clinical trial results for 2 new therapies for MS have been reported. Dimethyl fumarate, also known by its investigational name BG-12, became the third oral disease-modifying therapy for MS to be Food and Drug Administration (FDA)-approved in March 2013. Interestingly, dimethyl fumarate served as the active compound used for the treatment of psoriasis for decades. Alemtuzumab remains under investigation and is not currently FDA-approved for treatment of MS. Other drugs currently approved for alternative indications are being investigated for use in MS. Additionally, an investigation of alternative dosing strategies for glatiramer acetate suggests that patients may benefit from a higher dose formulation and less frequent medication administration. Advances in basic science research have identified another potential autoantigenic target in MS, KIR4.1, which may provide further insight into MS pathophysiology.
    Language English
    Publishing date 2013-10-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2645818-4
    ISSN 2163-0933 ; 2163-0402
    ISSN (online) 2163-0933
    ISSN 2163-0402
    DOI 10.1212/CPJ.0b013e3182a78f94
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.

    Boster, Aaron L / Ford, Corey C / Neudorfer, Orit / Gilgun-Sherki, Yossi

    Expert review of neurotherapeutics

    2015  Volume 15, Issue 6, Page(s) 575–586

    Abstract: Glatiramer acetate (GA) is approved for relapsing-remitting multiple sclerosis in 57 countries worldwide, with more than 2 million patient-years of exposure and over 20 years of continuous clinical use without new safety concerns. GA has an overall ... ...

    Abstract Glatiramer acetate (GA) is approved for relapsing-remitting multiple sclerosis in 57 countries worldwide, with more than 2 million patient-years of exposure and over 20 years of continuous clinical use without new safety concerns. GA has an overall favorable risk-benefit profile: 30% reduced annual relapse rate and decreased brain lesion activity. In clinically definite MS or clinically isolated syndrome, GA slows brain atrophy, which may be related to its unique anti-inflammatory and neuroprotective mechanisms of action. Early treatment with GA delays the onset of clinically definite MS more effectively than late treatment in clinically isolated syndrome. GA is not associated with immunosuppression, autoimmune disease, infections or development of neutralizing antibodies. A new three-times-weekly formulation of GA is available to potentially reduce the incidence of injection-related side effects. Other safety advantages of GA include its pregnancy rating (Category B) and limited uncontrolled data suggesting that tolerability is similar in children with MS.
    MeSH term(s) Antirheumatic Agents/therapeutic use ; Female ; Glatiramer Acetate/therapeutic use ; Humans ; Longitudinal Studies ; Male ; Multiple Sclerosis, Relapsing-Remitting/drug therapy ; Pregnancy
    Chemical Substances Antirheumatic Agents ; Glatiramer Acetate (5M691HL4BO)
    Language English
    Publishing date 2015-06
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2112534-X
    ISSN 1744-8360 ; 1473-7175
    ISSN (online) 1744-8360
    ISSN 1473-7175
    DOI 10.1586/14737175.2015.1040768
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Pharmacotherapy of multiple sclerosis: the PROOF trial.

    Boster, Aaron / Racke, Michael K

    Expert opinion on pharmacotherapy

    2009  Volume 10, Issue 8, Page(s) 1235–1237

    Abstract: Background: Currently approved disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) include two different interferon beta-1a (IFNB-1a) preparations: subcutaneous IFNB-1a (Rebif) 44 microg three times weekly and intramuscular ... ...

    Abstract Background: Currently approved disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) include two different interferon beta-1a (IFNB-1a) preparations: subcutaneous IFNB-1a (Rebif) 44 microg three times weekly and intramuscular IFNB-1a (Avonex) 30 microg once weekly.
    Objective: This evaluation is of the Prospective and Retrospective Long-Term Observational Study of Avonex and Rebif (PROOF), which intended to compare relative efficacy and tolerability of the two INFB-1a products.
    Methods: PROOF was analyzed in light of previous head-to-head studies comparing high- and low-frequency IFNB therapies.
    Results/conclusions: Several limitations, including a retrospective-prospective design, retrospective assessment of variables without predefined criteria, limited prospective evaluation, and inadequate sample size, necessitate careful interpretation of their Results. Ultimately, the question of long-term efficacy of high- versus low-frequency INFB therapies remains unanswered.
    MeSH term(s) Humans ; Injections, Subcutaneous ; Interferon Type I/administration & dosage ; Interferon Type I/therapeutic use ; Multiple Sclerosis/drug therapy ; Prospective Studies ; Recombinant Proteins ; Retrospective Studies
    Chemical Substances Interferon Type I ; Recombinant Proteins
    Language English
    Publishing date 2009-06
    Publishing country England
    Document type Editorial ; Research Support, N.I.H., Extramural
    ZDB-ID 2001535-5
    ISSN 1744-7666 ; 1465-6566
    ISSN (online) 1744-7666
    ISSN 1465-6566
    DOI 10.1517/14656560902927856
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.

    Nicholas, Jacqueline Ann / Racke, Michael Karl / Imitola, Jamie / Boster, Aaron Lee

    Therapeutic advances in chronic disease

    2014  Volume 5, Issue 2, Page(s) 62–68

    Abstract: Natalizumab (NTZ) is a highly effective disease modifying therapy for the treatment of relapsing forms of multiple sclerosis (MS). Despite evidence to support its use as first-line therapy, risk of NTZ-associated progressive multifocal ... ...

    Abstract Natalizumab (NTZ) is a highly effective disease modifying therapy for the treatment of relapsing forms of multiple sclerosis (MS). Despite evidence to support its use as first-line therapy, risk of NTZ-associated progressive multifocal leukoencephalopathy (PML) has largely contributed to it being relegated to a second-line position. Recent preliminary data may allow for a more accurate analysis of JC virus (JCV) risk stratification of a given patient's PML risk. Herein we propose an algorithm to help guide clinicians through this decision-making process. We recommend that NTZ be considered for first-line use in JCV antibody negative MS patients, JCV 'low positive' MS patients without prior exposure to immunosuppression and for a limited period (12-24 months) in JCV 'high positive' MS patients with an aggressive disease course . We caution against first-line use in JCV antibody 'high positive' patients beyond 12-24 months and any JCV antibody positive patient with a history of prior immunosuppression.
    Language English
    Publishing date 2014-02-05
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2554816-5
    ISSN 2040-6231 ; 2040-6223
    ISSN (online) 2040-6231
    ISSN 2040-6223
    DOI 10.1177/2040622313514790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data.

    Nicholas, Jacqueline / Boster, Aaron / Wu, Ning / Yeh, Wei-Shi / Fay, Monica / Kendter, Jon / Huang, Ming-Yi / Lee, Andrew

    PharmacoEconomics - open

    2018  Volume 2, Issue 1, Page(s) 31–41

    Abstract: Background: Data on comparative healthcare resource utilization and costs associated with the newer oral disease-modifying therapies (DMTs) for managing relapsing-remitting multiple sclerosis (MS) in routine clinical practice are limited. The purpose of ...

    Abstract Background: Data on comparative healthcare resource utilization and costs associated with the newer oral disease-modifying therapies (DMTs) for managing relapsing-remitting multiple sclerosis (MS) in routine clinical practice are limited. The purpose of this study was to estimate healthcare resource utilization, costs, and relapse rates in the year after initiating treatment with dimethyl fumarate (DMF), interferon (IFN)-β, glatiramer acetate (GA), teriflunomide, or fingolimod in routine clinical practice for patients with MS who did not receive a DMT in the previous year.
    Methods: Patients initiating DMF, IFNβ, GA, teriflunomide, or fingolimod were identified based on claims data from 2012 to 2015 in the Truven MarketScan Commercial Claims Databases (n = 4194). Healthcare resource utilization assessment included the proportion of patients who were hospitalized, or had emergency room (ER) or urgent care (UC) visits. Healthcare costs were estimated for 1 year before and 1 year after DMT initiation. Relapse episodes were identified based on a published claims-based algorithm and clinical input from the research investigators.
    Results: After DMT initiation, significant reductions in the proportions of patients who were hospitalized or requiring ER/UC visits were observed in all patient cohorts (p < 0.001 and p < 0.05, respectively). Non-prescription medical costs decreased after DMT initiation, with the largest decrease observed in the DMF cohort (US$5761 reduction, p < 0.0001). Reductions in non-prescription medical costs were associated with decreased use of outpatient services and inpatient hospital stays, and have the potential to partially offset DMT costs.
    Conclusions: DMT initiation is associated with reductions in healthcare resource utilization and non-prescription medical costs in routine clinical practice.
    Language English
    Publishing date 2018-02-20
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2874287-4
    ISSN 2509-4254 ; 2509-4262
    ISSN (online) 2509-4254
    ISSN 2509-4262
    DOI 10.1007/s41669-017-0035-2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top